Inviga Healthcare Fund acquires 21% stake in Forus Health

Inviga Healthcare Fund (IHF), the private equity platform founded by Dr. B. S. Ajaikumar of HCG, has acquired a 21% stake in Bengaluru-based Forus Health, an ophthalmic diagnostics pioneer whose devices have screened over 22 million patients across 75+ countries. Forus Health’s comprehensive digital platform integrated with artificial intelligence (AI) for Ocular & Oculomics has helped deliver last mile comprehensive eye diagnostics to over 5M+ patients across the world.

The secondary transaction signals Inviga’s intent to back world-class, AI-driven diagnostic solutions designed and built in India, and deployed globally at scale. This marks Inviga’s second major investment following its backing of Mynvax in 2024.

Founded by Dr. B. S. Ajaikumar, a doctor-preneur and Chairman of HealthCare Global Enterprises (HCG), Inviga Healthcare Fund invests in high-impact healthcare ventures and champions Indian healthcare entrepreneurial talent. Its mission is to build sustainable, accessible, and outcome-driven healthcare platforms that blend clinical excellence with scalable innovation.

Forus Health is founded by K. Chandrasekhar, an industry veteran with exceptional experience in health-tech & semiconductor industries. The company is best known worldwide for its 3nethra series of ophthalmic screening devices that have improved access to affordable eye care across the world. In 2025, Forus Health was listed among TIME Magazine’s World’s Top 400 HealthTech Companies for its significant impact on making vision care more widely accessible through technology. The Forus platform now offers an integrated digital solution for managing comprehensive eye health. Its latest product, 3nethra specto, is the world’s first wearable digital refractor controlled by a smartphone, enabling remote and tele-optometry services.

The global burden of preventable blindness underscores the importance of scalable eye-care innovation. It is estimated that over 270 million Indians live with some form of visual impairment, a majority of which is preventable through early detection. With around 100 million diabetics, nearly one in five are at risk of diabetic retinopathy (DR), while 3.5 million preterm births annually place nearly 2 million infants at risk of retinopathy of prematurity (ROP)—both leading causes of avoidable blindness. Globally, over 2.2 billion people suffer from vision impairment or blindness, of which more than 1 billion cases are preventable or treatable. The challenge extends even to high-income countries, where aging populations and diabetes continue to drive incidence despite advanced health systems. Forus Health’s advancements have helped bridge these diagnostic gaps worldwide, improving access to affordable, portable, and early-stage eye screening solutions across both emerging and developed markets.